X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DIVIS LABORATORIES PLETHICO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -1.1 17.8 - View Chart
P/BV x 0.0 3.9 0.4% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 PLETHICO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DIVIS LABORATORIES
Mar-16
PLETHICO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3952,484 15.9%   
Low Rs31918 3.4%   
Sales per share (Unadj.) Rs604.4142.3 424.9%  
Earnings per share (Unadj.) Rs32.541.9 77.5%  
Cash flow per share (Unadj.) Rs51.346.3 110.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs473.6161.5 293.2%  
Shares outstanding (eoy) m34.08265.47 12.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.412.0 2.9%   
Avg P/E ratio x6.640.6 16.2%  
P/CF ratio (eoy) x4.236.7 11.3%  
Price / Book Value ratio x0.510.5 4.3%  
Dividend payout %023.9 0.0%   
Avg Mkt Cap Rs m7,262451,525 1.6%   
No. of employees `000NA3.7 0.0%   
Total wages/salary Rs m1,5963,649 43.7%   
Avg. sales/employee Rs ThNM10,184.4-  
Avg. wages/employee Rs ThNM984.1-  
Avg. net profit/employee Rs ThNM2,998.5-  
INCOME DATA
Net Sales Rs m20,59837,764 54.5%  
Other income Rs m386848 45.5%   
Total revenues Rs m20,98438,612 54.3%   
Gross profit Rs m2,81814,138 19.9%  
Depreciation Rs m6421,182 54.3%   
Interest Rs m1,59323 6,867.2%   
Profit before tax Rs m96913,781 7.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1382,662 -5.2%   
Profit after tax Rs m1,10711,119 10.0%  
Gross profit margin %13.737.4 36.5%  
Effective tax rate %-14.319.3 -74.0%   
Net profit margin %5.429.4 18.3%  
BALANCE SHEET DATA
Current assets Rs m18,87730,947 61.0%   
Current liabilities Rs m11,8965,195 229.0%   
Net working cap to sales %33.968.2 49.7%  
Current ratio x1.66.0 26.6%  
Inventory Days Days36117 30.8%  
Debtors Days Days19885 232.3%  
Net fixed assets Rs m9,86117,027 57.9%   
Share capital Rs m341531 64.2%   
"Free" reserves Rs m12,33142,341 29.1%   
Net worth Rs m16,13942,877 37.6%   
Long term debt Rs m4,7065 100,123.4%   
Total assets Rs m33,14649,684 66.7%  
Interest coverage x1.6595.0 0.3%   
Debt to equity ratio x0.30 266,007.7%  
Sales to assets ratio x0.60.8 81.8%   
Return on assets %8.122.4 36.3%  
Return on equity %6.925.9 26.4%  
Return on capital %12.332.2 38.2%  
Exports to sales %21.485.3 25.1%   
Imports to sales %15.222.9 66.4%   
Exports (fob) Rs m4,40232,198 13.7%   
Imports (cif) Rs m3,1368,654 36.2%   
Fx inflow Rs m4,40232,270 13.6%   
Fx outflow Rs m3,1848,775 36.3%   
Net fx Rs m1,21923,496 5.2%   
CASH FLOW
From Operations Rs m2,43710,379 23.5%  
From Investments Rs m-6,265-4,135 151.5%  
From Financial Activity Rs m2,490-6,241 -39.9%  
Net Cashflow Rs m-1,3373 -40,520.0%  

Share Holding

Indian Promoters % 82.7 52.0 159.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 11.8 36.4%  
FIIs % 5.5 19.0 28.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.2 43.6%  
Shareholders   10,665 31,796 33.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS